沃华医药：2025年实现净利润9571.53万元，同比增长162.93%

Core Insights - The core viewpoint of the article highlights the financial performance of WoHua Pharmaceutical in its 2025 annual report, showcasing significant growth in revenue and net profit [1] Financial Performance - WoHua Pharmaceutical reported a total revenue of 816.95 million yuan, representing a year-on-year increase of 6.96% [1] - The net profit attributable to shareholders reached 95.72 million yuan, marking a substantial year-on-year growth of 162.93% [1] Product Line Performance - Revenue from cardiovascular system drugs amounted to 568.81 million yuan, with a year-on-year growth of 12.31% [1] - Revenue from musculoskeletal system drugs was 182.50 million yuan, showing a slight decline of 2.03% year-on-year [1] - Revenue from antiviral respiratory system drugs reached 26.09 million yuan, reflecting a year-on-year increase of 18.46% [1]